Sandra J. Lewis
Research Subjects
Sandra J. Lewis has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J Green
Midwestern Endocrinology, Overland Park, KS, USA
1 shared publication - Debbra D Bazata
St. Luke's Primary Care South, Overland Park, KS, USA
1 shared publication Deborah A. Anzalone
C AstraZeneca , Wilmington , DE , USA
1 shared publicationElisabetta Malangone-Monaco
D Truven Health Analytics, an IBM Company , Ann Arbor , MI , USA
1 shared publication- Harold Edward Bays
Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
1 shared publication - James R. Gavin
Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication
Latest Publications
- 21 February 2018
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (10) , 1717-1723
LDL cholesterol levels after switch from atorvastatin to rosuvastatin
(2018). LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current Medical Research and Opinion: Vol. 34, No. 10, pp. 1717-1723.
- 21 February 2018
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (10) , 1717-1723
LDL cholesterol levels after switch from atorvastatin to rosuvastatin
(2018). LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current Medical Research and Opinion: Vol. 34, No. 10, pp. 1717-1723.
- Open Access
- 1 August 2011
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 7, 525-34
Lipid-lowering therapy: who can benefit
Peer reviewed article authored by (Lewis SJ). Read article or submit your manuscript for publishing.
- 1 August 2011
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 7, 525-34
Open AccessLipid-lowering therapy: who can benefit
Peer reviewed article authored by (Lewis SJ). Read article or submit your manuscript for publishing.
- 1 November 2009
- Vol. 58, S32-40
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Low-density lipoprotein cholesterol and coronary heart disease: the importance of reaching target goals with statin therapy.
While Managing Acute-Care Issues, family physicians are challenged daily to recognize and treat modifiable risk factors for coronary heart disease (CHD) and to educate patients on the importance of risk reduction. Time constraints and the imperatives of immediate issues make the challenge of identification and treatment of CHD risk difficult. A stunning number of family medicine patients present with 1 or more of the following CHD risk factors: low-density lipoprotein cholesterol (LDL-C) =130 mg/dL (33% of American adults), total cholesterol =200 mg/dL (45%), hypertension (33%), tobacco use (21%), sedentary lifestyle (69%), excessive body weight (body mass index =25; 67%), diabetes (8%), or pre-diabetes (26%). The objective of comprehensive therapeutic interventions in CHD, from diet and lifestyle changes, to smoking cessation, to medications, is to prevent new (primary prevention) or recurrent (secondary prevention) cardiovascular events, with the ultimate goal of preventing disability and death. Family physicians have the distinct advantage of seeing patients' health status from a global perspective, giving them a greater opportunity to recognize risk and initiate preventive interventions. Although therapeutic efforts have been directed traditionally at patients with established CHD and asymptomatic patients at high risk for cardiac events, new data are emerging that suggest that earlier, more aggressive treatment increases clinical benefit. This article (1) reviews the importance of reaching target goals for LDL-C and other biomarkers of risk in the primary and secondary prevention of CHD, and (2) addresses dosing issues and other practical methods of identifying and treating family medicine patients who are at risk.
- 1 November 2009
- Vol. 58, S32-40
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Low-density lipoprotein cholesterol and coronary heart disease: the importance of reaching target goals with statin therapy.
While Managing Acute-Care Issues, family physicians are challenged daily to recognize and treat modifiable risk factors for coronary heart disease (CHD) and to educate patients on the importance of risk reduction. Time constraints and the imperatives of immediate issues make the challenge of identification and treatment of CHD risk difficult. A stunning number of family medicine patients present with 1 or more of the following CHD risk factors: low-density lipoprotein cholesterol (LDL-C) =130 mg/dL (33% of American adults), total cholesterol =200 mg/dL (45%), hypertension (33%), tobacco use (21%), sedentary lifestyle (69%), excessive body weight (body mass index =25; 67%), diabetes (8%), or pre-diabetes (26%). The objective of comprehensive therapeutic interventions in CHD, from diet and lifestyle changes, to smoking cessation, to medications, is to prevent new (primary prevention) or recurrent (secondary prevention) cardiovascular events, with the ultimate goal of preventing disability and death. Family physicians have the distinct advantage of seeing patients' health status from a global perspective, giving them a greater opportunity to recognize risk and initiate preventive interventions. Although therapeutic efforts have been directed traditionally at patients with established CHD and asymptomatic patients at high risk for cardiac events, new data are emerging that suggest that earlier, more aggressive treatment increases clinical benefit. This article (1) reviews the importance of reaching target goals for LDL-C and other biomarkers of risk in the primary and secondary prevention of CHD, and (2) addresses dosing issues and other practical methods of identifying and treating family medicine patients who are at risk.
- 1 January 2009
- Published by Elsevier in The American Journal of Medicine
- Vol. 122 (1) , S38-S50
Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008
- 1 January 2009
- Published by Elsevier in The American Journal of Medicine
- Vol. 122 (1) , S38-S50
Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008
- Open Access
- 3 October 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 277
Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)
Background: Studies derived from continuous national surveys have shown that the prevalence of diagnosed diabetes mellitus in the US is increasing. This study estimated the prevalence in 2004 of self-reported diagnosis of diabetes and other conditions in a community-based population, using data from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Methods: The initial screening questionnaire was mailed in 2004 to a stratified random sample of 200,000 households in the US, to identify individuals, age ≥ 18 years of age, with diabetes or risk factors associated with diabetes. Follow-up disease impact questionnaires were then mailed to a representative, stratified random sample of individuals (n = 22,001) in each subgroup of interest (those with diabetes or different numbers of risk factors for diabetes). Estimated national prevalence of diabetes and other conditions was calculated, and compared to prevalence estimates from the National Health and Nutrition Examination Survey (NHANES) 1999–2002. Results: Response rates were 63.7% for the screening, and 71.8% for the follow-up baseline survey. The SHIELD screening survey found overall prevalence of self-reported diagnosis of diabetes (either type 1 or type 2) was 8.2%, with increased prevalence with increasing age and decreasing income. In logistic regression modeling, individuals were more likely to be diagnosed with type 2 diabetes if they had abdominal obesity (odds ratio [OR] = 3.50; p < 0.0001), BMI ≥28 kg/m2 (OR = 4.04; p < 0.0001), or had been diagnosed with dyslipidemia (OR = 3.95; p < 0.0001), hypertension (OR = 4.82; p < 0.0001), or with cardiovascular disease (OR = 3.38; p < 0.0001). Conclusion: The SHIELD design allowed for a very large, community-based sample with broad demographic representation of the population of interest. When comparing results from the SHIELD screening survey (self-report only) to those from NHANES 1999–2002 (self-report, clinical and laboratory evaluations), the prevalence of diabetes was similar. SHIELD allows the identification of respondents with and without a current diagnosis of the illness of interest, and potential longitudinal evaluation of risk factors for future diagnosis of that illness.
- 3 October 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 277
Open AccessPrevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)
Background: Studies derived from continuous national surveys have shown that the prevalence of diagnosed diabetes mellitus in the US is increasing. This study estimated the prevalence in 2004 of self-reported diagnosis of diabetes and other conditions in a community-based population, using data from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Methods: The initial screening questionnaire was mailed in 2004 to a stratified random sample of 200,000 households in the US, to identify individuals, age ≥ 18 years of age, with diabetes or risk factors associated with diabetes. Follow-up disease impact questionnaires were then mailed to a representative, stratified random sample of individuals (n = 22,001) in each subgroup of interest (those with diabetes or different numbers of risk factors for diabetes). Estimated national prevalence of diabetes and other conditions was calculated, and compared to prevalence estimates from the National Health and Nutrition Examination Survey (NHANES) 1999–2002. Results: Response rates were 63.7% for the screening, and 71.8% for the follow-up baseline survey. The SHIELD screening survey found overall prevalence of self-reported diagnosis of diabetes (either type 1 or type 2) was 8.2%, with increased prevalence with increasing age and decreasing income. In logistic regression modeling, individuals were more likely to be diagnosed with type 2 diabetes if they had abdominal obesity (odds ratio [OR] = 3.50; p < 0.0001), BMI ≥28 kg/m2 (OR = 4.04; p < 0.0001), or had been diagnosed with dyslipidemia (OR = 3.95; p < 0.0001), hypertension (OR = 4.82; p < 0.0001), or with cardiovascular disease (OR = 3.38; p < 0.0001). Conclusion: The SHIELD design allowed for a very large, community-based sample with broad demographic representation of the population of interest. When comparing results from the SHIELD screening survey (self-report only) to those from NHANES 1999–2002 (self-report, clinical and laboratory evaluations), the prevalence of diabetes was similar. SHIELD allows the identification of respondents with and without a current diagnosis of the illness of interest, and potential longitudinal evaluation of risk factors for future diagnosis of that illness.
- 7 May 2007
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 1 (2) , 159-166
Perspectives and current strategies for dyslipidemia in women
- 7 May 2007
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 1 (2) , 159-166
Perspectives and current strategies for dyslipidemia in women
- 1 February 2007
- Vol. 52, 147-51
Risk of cardiovascular disease as a woman ages.
The prevalence of heart disease and hypertension are increased in postmenopausal women. Gynecologists who have the role of primary care clinicians need to be aware of these risks and recognize cardiovascular problems in their patients.
- 1 February 2007
- Vol. 52, 147-51
Risk of cardiovascular disease as a woman ages.
The prevalence of heart disease and hypertension are increased in postmenopausal women. Gynecologists who have the role of primary care clinicians need to be aware of these risks and recognize cardiovascular problems in their patients.
- 1 February 2007
- Published by Elsevier in American Heart Journal
- Vol. 153 (2) , 182-188
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
- 1 February 2007
- Published by Elsevier in American Heart Journal
- Vol. 153 (2) , 182-188
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?